Haemonetics Stock Climbs As Analysts Hike Price Targets

Haemonetics Corporation’s stocks have been trading up by 15.77 percent, driven primarily by strong earnings momentum and upgraded guidance.

Live Update At 16:46:51 EDT: On Tuesday, August 18, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 15.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Haemonetics Corporation, ticker HAE, has quietly turned into a momentum name on the back of strong fundamentals. In fiscal Q1, Haemonetics delivered net revenue of $339.4M, well ahead of the $327.9M Wall Street mark. That is not a rounding error. It shows real demand across its core blood and plasma franchises.

On the bottom line, HAE printed adjusted EPS of $1.14 versus $0.87 expected. That kind of beat tells traders there is both operating leverage and cost discipline. The latest quarter’s total revenue of $339.38M produced gross profit of about $202.8M, translating to a hefty 59% gross margin. For a med‑tech name, that margin profile gives room to fund R&D and still drive earnings growth.

More Breaking News

• Aurora Innovation AUR Slides As Loss Widens And Insiders Prep Sales
• CIFR Stock Draws Bullish Targets As HPC Story Builds
• BTBT Stock Grinds Sideways As Traders Eye Next Break
• Duolingo Stock Rebounds As Q2 Beat Fuels Bullish Targets

Valuation is not cheap, with a P/E near 43.9 and price‑to‑sales around 3.1, but the market is paying for growth and consistency. Revenue has been climbing, with multi‑year growth in the mid‑single to high‑single digits. HAE’s balance sheet shows a current ratio of 3.1 and interest coverage above 21x, giving the company flexibility despite higher leverage. For active traders, this mix of growth, margins, and balance‑sheet strength sets the stage for continued rerating as long as execution holds.

Why Traders Are Watching HAE Momentum

The tape confirms what the earnings and guidance are saying. Over the past few weeks, HAE has broken out from the upper $70s and low $80s into triple digits. On 2026/07/24, shares closed at $78.78. By 2026/08/18, HAE finished at $104.65 after trading as high as $106.67. That is a sharp trend higher, with a series of higher lows from $78 to $80, then into the high $80s and low $90s, before the recent breakout.

Intraday action on the latest session shows tight, controlled trading rather than a wild spike. After an early range between roughly $102 and $105, HAE spent most of the day consolidating between $104 and $106, closing near the high end of that band. For momentum traders, that kind of grind higher with shallow pullbacks often signals strong hands are in control.

The story underneath the chart is driving that demand. Haemonetics is gaining market share in Plasma, keeping Blood Management Technologies growing, and getting Interventional Technologies back to expansion. Management responded to the Q1 strength by nudging FY27 guidance higher, taking both revenue and EPS growth outlooks to 5%–8%. That is not a hype‑driven raise; it is a steady, confidence‑driven bump that longer‑term traders respect.

Wall Street is leaning into the story. Bank of America lifted its HAE target from $93 to $100 after hosting the CEO and repeated a Buy rating, talking about “best‑in‑class performance” and a potential valuation rerating by FY27. Raymond James went even more aggressive, hiking its target to $105 with an Outperform call. Baird pushed its target to $96, also with Outperform, highlighting a “larger‑than‑expected” Q1 beat and the guidance raise. Barrington Research moved from $89 to $95 and is now more optimistic about Haemonetics’ profitability and its path to cut debt by 2027. Even Citi, staying Neutral, raised its target from $79 to $92, while broader Street consensus has drifted toward about $96.90.

For traders, that cluster of target hikes around the same time often fuels short‑term follow‑through as algos and discretionary funds recalibrate models and allocations.

Conclusion

For active traders studying HAE, the setup is now a classic strong‑earnings, strong‑guidance, strong‑trend picture. Haemonetics beat Q1 on both the top and bottom line, then backed it up with a modest but meaningful guidance lift out to FY27. The company is putting up 59% gross margins, solid cash flow of roughly $52.3M from operations in the latest quarter, and $44.4M in free cash flow. Debt remains elevated, but analysts like Barrington explicitly point to improving profitability and the ability to reduce leverage by fiscal 2027.

On the Street side, Bank of America’s $100 target, Raymond James at $105, Baird at $96, and Barrington at $95 send one clear message to traders watching HAE: expectations are moving higher. Citi’s Neutral stance and $92 target add some restraint, reminding traders that valuation is demanding and execution needs to stay tight.

From a trading perspective, HAE has already made a big move off the $70s and $80s, so chasing blindly makes little sense for disciplined players. This is where preparation and rule‑based trading matter most. As Tim Sykes loves to remind his students, “The market doesn’t owe you anything — you earn every dollar by managing risk, cutting losses quickly, and only trading the best setups.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” Haemonetics is shaping up as one of those high‑quality stories right now, but the edge still comes from your plan, not the hype. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.